NeuroSense Therapeutics (NRSN) Stock Analysis: AI Score & Alternative Data
Demand signals are heating up for NeuroSense Therapeutics
Is NeuroSense Therapeutics a buy right now? The alternative data says hold. This NRSN stock analysis is built on the 25+ alternative data signals AltIndex tracks on NeuroSense Therapeutics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 46/100: a Hold. The stock trades at $0.47 with a $18M market cap.
The data leans positive over the past 90 days — web traffic up 169.3% to 8K monthly visits, and sentiment up 43.5% to 89/100 — but the move hasn’t been broad enough to lift NRSN into buy territory yet.
NRSN’s broader alt-data profile also covers headcount (28 employees, according to LinkedIn), business outlook (46% of employees positive), and Facebook followers (2K). Every signal links to its own page with full history, the NRSN technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on NRSN is just below.
NeuroSense Therapeutics AI Stock Analysis
NeuroSense Therapeutics is a clinical-stage biotechnology company that is engaged in the development of novel therapies for the treatment of neurodegenerative diseases. The company's flagship product is aimed at treating amyotrophic lateral sclerosis (ALS), a progressive nervous system disease.
Analysis generated July 31, 2026.
Recent NeuroSense Therapeutics Stock Alerts
|
NeuroSense Therapeutics | August 6 Price is down by -8.6% in the last 24h. |
|
NeuroSense Therapeutics | August 5 Price is up by 9.6% in the last 24h. |
|
NeuroSense Therapeutics | August 4 Price is up by 6.2% in the last 24h. |
|
NeuroSense Therapeutics | August 3 Price is down by -13.9% in the last 24h. |
NeuroSense Therapeutics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 8K | 169.3% | |
| LinkedIn Employees | 28 | N/A | |
| Employee Recommend | 46 | N/A | |
| Business Outlook | 46 | N/A | |
| Sentiment | 89 | 43.5% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 4 | N/A | |
| Stocktwits Mentions | 51 | 104.0% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 4K | 0.6% | |
| Instagram Followers | 2K | 0% | |
| Facebook Followers | 2K | 0% | |
| Facebook Engagement | 0 | N/A |
About NeuroSense Therapeutics (NRSN)
Neurosense Therapeutics Ltd (NRSN) is a pioneering clinical-stage biotechnology company committed to transforming the landscape of neurodegenerative disease treatment, particularly focusing on Parkinson's disease. Leveraging its proprietary development platform, Neurosense is advancing a robust pipeline of innovative therapeutic candidates currently in pivotal clinical trials, addressing substantial unmet medical needs in neurology. With a seasoned management team and strategic collaborations, the company is poised to deliver cutting-edge therapies that significantly improve patient outcomes and strengthen its position within the biopharmaceutical sector.
| Price | $0.47 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $18M |
| Year Range | $0 – $1 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest NeuroSense Therapeutics News
View more → |
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health CanadaAugust 6 - PRNewswire |
 |
The Next Billion-Dollar Opportunity in Alzheimer's Disease Market: 6 Pipeline Therapies to Watch | DelveInsightAugust 6 - PRNewswire |
|
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALSJuly 22 - PRNewswire |
|
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"July 6 - PRNewswire |
 |
NeuroSense’s ALS drug cuts key biomarker in Phase IIb trialJune 29 - Biztoc.com |
NeuroSense Therapeutics Earnings & Financial Performance
View all earnings →NeuroSense Therapeutics Insider Trading Activity
View all →| No recent insider transactions on file. |
NeuroSense Therapeutics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to NeuroSense Therapeutics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Sensei BiotherapeuticsSNSE |
$13.85 6.5% | $17M | 64 |
 |
LipocineLPCN |
$2.06 1.4% | $17M | 57 |
 |
Werewolf TherapeuticsHOWL |
$0.38 0.5% | $19M | 41 |
 |
PluriPLUR |
$1.63 7.1% | $19M | 42 |
 |
Vyne TherapeuticsVYNE |
$28.56 12.2% | $19M | 49 |
Explore NeuroSense Therapeutics Data
Frequently Asked Questions: NeuroSense Therapeutics (NRSN)
NeuroSense Therapeutics has an AltIndex AI Score of 46/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
46/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of NeuroSense Therapeutics (NRSN) stock is $0.47 with a market cap of $18M.
As of today, NeuroSense Therapeutics’s PE (Price to Earnings) ratio is —.
View the latest NeuroSense Therapeutics insider transactions to see recent buying and selling activity by company executives and directors.
Check the NeuroSense Therapeutics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The NRSN stock price chart above shows NeuroSense Therapeutics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full NeuroSense Therapeutics technical analysis for RSI, moving averages, and more.
See the stocks similar to NeuroSense Therapeutics section on this page for companies in the same industry ranked by market cap and AI Score.
